[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemifacial-spasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemifacial-spasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100531088","phase-4-effects-of-daxibotulinumtoxina-for-blepharospasm-and-hemifacial-spasm-100531088",false,"NCT06195241","Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm","The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm","Inclusion Criteria:\n\n* Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by an ophthalmologist.\n* No known neurologic or neuromuscular systematic medications.\n* No history or surgical intervention for BEB or HFS.\n* Patients are required to have a minimum score of 4 out of 8 on the modified Jankovic Rating Scale for Severity\u002FFrequency.\n\nExclusion Criteria:\n\n* Patients will be excluded if age \\\u003C 18, are pregnant, are non-willing, or have contra-indications to botulinum toxin.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:\n\n1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?\n2. What percentage of patients achieve a clinical response?\n\nParticipants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.",[26,27],"Benign Essential Blepharospasm","Hemifacial Spasm","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-23","ACTUAL",{"date":34,"type":32},"2025-02-11",{"date":36,"type":20},"2027-03",{"name":38,"class":39},"Montefiore Medical Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":5},"100603323","prospective-register-study-to-assess-eligibility-for-and-efficacy-of-surgical-treatment-in-patients-with-neurovascular-conflict-100603323","NCT07135024","Prospective Register Study to Assess Eligibility for and Efficacy of Surgical Treatment in Patients With nEuRovascular Conflict","PETER registry","Inclusion Criteria:\n\n* suspected neurovascular conflict\n* signed consent for further use of routine clinical data as accepted by local regulations\n\nExclusion Criteria:\n\n* refusal of further use of routine clinical data",{"count":49,"type":20},5001,"5 Years","OBSERVATIONAL","The aim of the registry is a multicenter, prospective long-term data collection of patients suspected neurovascular conflict and referred for possible microvascular decompression (Jannetta procedure). The registry relies exclusively on routinely collected clinical data, which are gathered in a standardized and privacy-compliant manner as part of everyday clinical practice. By systematically compiling this information across multiple centers, valuable insights into the effectiveness, potential side effects, and long-term outcomes of this surgical treatment can be gained. The registry will serve as a foundation for future scientific analyses and is intended to help answer relevant research questions regarding the treatment of trigeminal neuralgia based on solid evidence.",[54,55,56,57,27,58],"Trigeminal Neuralgia","Tic Douloureux","Facial Pain","Glossopharyngeal Neuralgia","Neurovascular Conflict",[54,60,61,62,63,64,65,66,67,68,69,70,71],"Registry","prospective study","eligibility determination","efficacy, treatment","Follow-Up Studies","indication","microvascular decompression","Jannetta","tic douloureux","hemifacial spasm","neurovascular conflict","glossopharyngeal neuralgia","NOT_YET_RECRUITING","2025-08-13",{"date":75,"type":32},"2025-08-21",{"date":77,"type":20},"2025-10-01",{"date":79,"type":20},"2033-10-01",{"name":81,"class":39},"Gerrit A Schubert"]